The clinical use of porcine factor VIIi
Kernoff, P.B.
Progress in Clinical and Biological Research 324: 47-56
1990
ISSN/ISBN: 0361-7742 PMID: 2106692 Document Number: 352159
Extensive worldwide experience with PE-fractionated porcine factor VIII concentrate has confirmed the expectation that the produce has an important place in the management of hemophiliacs with inhibitors, and that the problems which constrained the use of the original animal factor VIII concentrates have been largely overcome. A particular advantage, compared with PCCs and derivatives, is that dosage and effects can be monitored with conventional coagulation tests.
Document emailed within 1 workday
Related Documents
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Gatti, L.; Mannucci, P.M. 1984: Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies Thrombosis and Haemostasis 51(3): 379-384
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Negrier, C. 1994: The use of porcine factor VIIi in France Seminars in Hematology 31(2 Suppl 4: 29-32
Yoshioka, A.; Shima, M.; Morichika, S.; Terada, S.; Fukui, H. 1994: The use of porcine factor VIIi in Japan Seminars in Hematology 31(2 Suppl 4: 26-28
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Gringeri, A.; Santagostino, E.; Tradati, F.; Giangrande, P.L.; Mannucci, P.M. 1991: Adverse effects of treatment with porcine factor VIIi Thrombosis and Haemostasis 65(3): 245-247
Hay, C.R. 2000: Porcine factor VIII: past, present and future Haematologica 85(10 Suppl): 21-24; Discussion: 24-25
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Hay, C.R.; Lozier, J.N.; Lee, C.A.; Laffan, M.; Tradati, F.; Santagostino, E.; Ciavarella, N.; Schiavoni, M.; Fukui, H.; Yoshioka, A.; Teitel, J.; Mannucci, P.M.; Kasper, C.K. 1996: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey Thrombosis and Haemostasis 75(1): 25-29
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Lee, C.A.; Owens, D.; Bray, G.; Giangrande, P.; Collins, P.; Hay, C.; Gomperts, E.; Schroth, P.; Barrowcliffe, T. 1999: Pharmacokinetics of recombinant factor VIIi (recombinate) using one-stage clotting and chromogenic factor VIIi assay Thrombosis and Haemostasis 82(6): 1644-1647
Mauser-Bunschoten, E.P.; Roosendaal, G.; Bruin, M.; van Dijken, P.J. 1990: Disappearance of factor VIIi antibodies upon frequent administration of factor VIIi Folia Haematologica 117(4): 533-537
Molinas, F.C.; Maiztegui, J.I. 1981: Factor VIII: C and factor VIIi R: Ag in Argentine hemorrhagic fever Thrombosis and Haemostasis 46(2): 525-527
Girolami, A.; de Marco, L.; Fabris, F.; Casonato, A. 1977: Platelet adhesiveness and aggregation in combined factor V and factor VIIi deficiency and in combined factor VIi and factor VIIi deficiency Folia Haematologica 104(5): 663-669